Tag: WuXi AppTec

PhoenixMD and WuXi STA Produced Multikilogram Drug Supply for TNBC Treatment

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices. Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designi...

WuXi AppTec Acquires Pharmapace

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced that it has acquired Pharmapace, Inc., a US-based clinical research se...

WuXi STA Passed First GMP Inspection by MPA

STA Pharmaceutical Co., Ltd., – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the Eu...

WuXi AppTec Passed Three Regulatory Inspections with Excellence

Three of WuXi AppTec Laboratory Testing Division’s facilities, Drug Safety Testing, Bioanalytical Services and Medical Device Testing, recently completed regulatory inspections from the US FDA (Food a...

WuXi STA and Ark Biosciences Team Up for CMC Development

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and development, especially in the area of ...

WuXi STA and BioLingus in Exclusive Technology Collaboration

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for subling...

Collaboration of Latvian and Chinese Companies

Chemspace and LabNetwork, a WuXi AppTec company, both online marketplaces for chemical compounds used in drug discovery, announced they have entered into a collaboration agreement. Under the agreement...

WuXi AppTec Expands US Facility

WuXi AppTec, headquartered in Shanghai, China, plans to expand its facilities in San Diego. WuXi AppTec describes itself as “a leading global pharmaceutical and medical device open-access capabilit...

WuXi AppTec Raises $1Billion after Debut on SSE

Chinese biotech WuXi AppTec has completed its listing on Hong Kong’s HKEX, raising $967m just months after making its debut on the Shanghai exchange. The company – which provides contract research,...

Schrödinger and Wuxi Apptec formed Faxian Therapeutics

drug-discovery
Schrödinger, a privately-held company revolutionizing drug discovery, and WuXi AppTec, a leading pharmaceutical and medical device company, announced that they have formed Faxian Therapeutics.

WuXi AppTec launches a new DNA technology to gear up drug discovery

dna
WuXi AppTec (China), a leading pharmaceutical and medical device technology platform company, launched a new DNA-Encoded Library (DEL) Construction & Screening Platform

WuXi STA will set up a new R&D Center

biotechnology
STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.

WuXi AppTec launches expanded Laboratory Testing Division in USA

laboratory
WuXi AppTec, a leading global pharmaceutical and medical device company, announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

Agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the USA

STA Pharmaceutical sees rapid growth in MAH programs in China

sta-pharmaceutical-logo
STA Pharmaceutical reports that it has seen a rapid uptake in companies with intent to market their products in China

STA Pharmaceutical to open new transition metal catalysis center in Changzhou, China

wuxi-sta-cover
The center will allow STA to introduce transition metal catalyst-screening technology to existing small molecule process development and manufacturing platform